ClinConnect ClinConnect Logo
Search / Trial NCT05177523

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Dec 15, 2021

Trial Information

Current as of July 25, 2025

Recruiting

Keywords

Axonal Damage Axonal Demyelination Axonal Degeneration Axonal Loss Axonal Disorganization Axonal Repair Axonal Remyelination Axonal Reorganization Advanced Mri (A Mri) Neurite Orientation Dispersion And Density Imaging (Noddi) Diffusion Kurtosis (Dk) Magnetization Transfer Imaging (Mti) Multi Echo Susceptibility Based Imaging (Sbi) Myelin Water Imaging (Mwi) T1 Relaxometry (Quantitative T1, Q T1) Machine Learning Technique

ClinConnect Summary

This clinical trial is investigating how nerve damage and repair processes work in different types of Multiple Sclerosis (MS). The researchers aim to understand the differences in the health of nerve fibers between patients with active relapsing-remitting MS and those with non-active progressive MS. They will use advanced imaging techniques over two years to track changes and validate their findings with tissue samples.

To participate, patients must be between 18 and 80 years old and have a confirmed diagnosis of either active relapsing-remitting MS with recent relapses or non-active progressive MS without recent relapses. Healthy volunteers in the same age range can also join the study, as long as they do not have any neurological or psychiatric disorders. Participants will undergo imaging scans and may be asked questions about their health. It’s important to note that individuals who are pregnant, have certain medical devices, or cannot undergo MRI scans cannot participate. This study is currently recruiting participants, and your involvement could help improve our understanding of MS and how to better treat it.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria for patients:
  • * Patients may be diagnosed with:
  • 1. active RRMS (n=100): Relapsing-remitting course and \> 1 clinical relapse and/or signs of MRI activity (\> 1 Gd enhancing lesion) during the last year before study enrollment.
  • 2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and/or signs of MRI activity during the last year before study enrollment.
  • Age 18-80 years old
  • No other neurological or psychiatric disorder
  • Inclusion criteria for healthy controls:
  • Age 18-80 years old
  • No other neurological or psychiatric disorder
  • Exclusion Criteria for patients and healthy controls:
  • Pregnancy
  • Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).
  • Inability to give consent

About University Hospital, Basel, Switzerland

The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.

Locations

Basel, , Switzerland

Patients applied

0 patients applied

Trial Officials

Cristina Granziera, Prof. Dr. med.

Principal Investigator

Department of Neurology, University Hospital Basel

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials